How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy.
Depression is conventionally viewed as a state of chemical imbalance, and antidepressants are suggested to act through increasing monoaminergic neurotransmission. These views are currently considered simplistic. This article examines the animal and human literature on the neurohistological mechanisms underlying stress, depression and antidepressant treatment. Pathological stress and depression are associated with changes such as loss of dendritic spines, shrinkage of the dendritic tree and loss of synapses in the hippocampus and prefrontal cortex. There is also a decrease in glia. Apoptosis may occur under extreme circumstances. In contrast, there is increased dendritic arborization and synaptogenesis in the amygdala. Antidepressant treatment protects against and even reverses some but not all of these stress-induced neurohistological changes. Pathological stress results in an aberrant neuroplasticity response characterized by abnormally increased activity in the amygdala and by impaired functioning of the hippocampus, prefrontal cortex and downstream structures. This aberrant neuroplasticity response directly explains most of the clinical symptoms of depression. Antidepressant treatment protects against stress-induced pathoplastic neurohistological and neurocognitive changes. Antidepressant treatment also restores functional neuroplasticity in stressed organisms and, thereby, presumably, facilitates re-adaptation through learning and memory mechanisms. Thus, the stress-depression syndrome and the therapeutic and prophylactic efficacy of antidepressant treatments can be explained through a hardwiring analogy. In this context, glutamate is an important neurotransmitter.
Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India.
Chittaranjan
C
Andrade
N Sanjay Kumar
NS
Rao
Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16655-60
20810923
Arch Gen Psychiatry. 2006 Aug;63(8):856-64
16894061
Bipolar Disord. 2002 Jun;4(3):183-94
12180273
Arch Gen Psychiatry. 2000 Jan;57(1):14-20
10632228
Eur Neuropsychopharmacol. 2009 May;19(5):329-38
19176277
Biol Psychiatry. 2000 Jun 15;47(12):1043-9
10862803
Pharmacol Rev. 2006 Mar;58(1):115-34
16507885
Biol Psychiatry. 2010 Jan 15;67(2):139-45
19897179
Neuroreport. 2004 Sep 15;15(13):2109-12
15486491
Neuropsychopharmacology. 2008 Jan;33(1):88-109
17851537
Eur J Neurosci. 2002 Jul;16(2):283-90
12169110
Biol Psychiatry. 2010 Mar 1;67(5):432-8
20074703
Acta Psychiatr Scand. 2010 Sep;122(3):192-210
20105149
Neuropsychopharmacology. 2005 Jan;30(1):27-34
15383831
Front Behav Neurosci. 2010 Feb 22;3:34
20204139
Brain Res. 2005 Nov 23;1063(1):32-9
16271709
Biol Psychiatry. 2006 Oct 15;60(8):874-81
16499878
Biol Psychiatry. 2002 Sep 1;52(5):386-92
12242054
Exp Neurol. 2000 Oct;165(2):231-6
10993683
Indian J Psychiatry. 2008 Oct;50(4):244-52
19823608
Neuropsychopharmacology. 2004 Aug;29(8):1538-45
15127079
Mol Psychiatry. 2008 Nov;13(11):993-1000
18504424
Rev Neurosci. 2002;13(1):59-84
12013026
Neuroscience. 2002;109(2):219-30
11801359
Neuron. 2010 Apr 29;66(2):198-204
20434997
J Psychiatry Neurosci. 2010 Sep;35(5):337-43
20731966
Arch Gen Psychiatry. 2000 Oct;57(10):925-35
11015810
Convuls Ther. 1990;6(4):318-319
11941087
Prog Neurobiol. 2009 Dec;89(4):369-82
19819293
Eur Neuropsychopharmacol. 2004 Dec;14 Suppl 5:S491-5
15550347
Arch Gen Psychiatry. 2006 Oct;63(10):1121-9
17015814